Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04685551
Other study ID # CancerDyads
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date July 1, 2021
Est. completion date December 31, 2024

Study information

Verified date July 2022
Source Charles Drew University of Medicine and Science
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This proposed intervention centers on improving survivorship outcomes among African American and Latinx cancer survivor and caregiver dyads. As a result, there will be four major outcomes. First, as a result of partnership with minority social institutions (e.g. faith leaders), we will develop an in-depth culturally sensitive curriculum and survivorship care plan for Cancer Survivorship and Caregiver Leaders Aimed for Minority Populations (CSC LAMPs). Second, we will increase knowledge and skills by evaluating a comprehensive cancer survivorship training program designed for underserved health professional students. Third, the implementation of this program will improve survivorship outcomes among African American and Latinx cancer survivors with advanced stage cancer and their caregivers. Lastly, this study will build sustainability for underserved minorities with the training of 30 future healthcare providers as a valuable community resource for improving cancer survivorship outcomes. The long-term outcomes of the CSC LAMPs program will generate workforce capacity and diversity in cancer-based clinical practice, research, and community advocacy for underserved minority cancer survivors and caregivers.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Aim 1 Focus Group for Cancer Survivors and Caregivers: Inclusion Criteria - Individuals ages 18 and older - identify as African American or Latinx - identify as a cancer survivor and/or caregiver - speak and/or understand English Exclusion Criteria - individuals ages 17 years or younger - does not identify as African American or Latinx - unable to speak or understand English - does not identify as a cancer survivor or caregiver Aim 1 Focus Group for Oncology Healthcare Providers: Inclusion Criteria - Individuals ages 18 and older - identify as a healthcare provider - provide care to cancer patients in current provider role - speak and/or understand English Exclusion Criteria - individuals ages 17 years or younger - unable to speak or understand English - does not provide care to cancer patients - does not identify as a healthcare provider Aim 2: Inclusion Criteria - Individuals ages 18 and older - registered as a CDU student - speak and/or understand English - considered to be underserved, which include a) identifying as an underrepresented minority: Asian, Pacific Islander, African American, Hispanic, and Native American/Alaskan Native and/or b) from a medically underserved population (i.e. faced economic, cultural or linguistic barriers to health care) Exclusion Criteria - individuals ages 17 years or younger - not registered as a CDU student - unable to speak or understand English - not considered to be underserved For Aim 3: Inclusion Criteria - cancer survivor with a participating caregiver - stage III or stage IV cancer diagnosis - breast, lung, or colorectal cancer diagnosis - identify as African American or Latinx - speak and/or understand English Exclusion Criteria - individuals ages 17 years or younger - does not identify as African American or Latinx - unable to speak or understand English - does not identify as a cancer survivor - cancer survivor does not identify a caregiver - does not have a breast, lung, or colorectal cancer diagnosis - not diagnosed with a stage III or stage IV cancer diagnosis

Study Design


Intervention

Behavioral:
Change in knowledge, motivation, skills, and resources
Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to improve survivorship outcomes.

Locations

Country Name City State
United States Charles R. Drew University of Medicine & Science Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Charles Drew University of Medicine and Science

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Increase in psychosocial well-being using the Quality of Life: Short Form Health Survey and the Center for Epidemiologic Studies Depression Scale By comparison from baseline to post-intervention, there will be a 25% increase in the psychosocial well-being among study participants. 3 months
Primary Reduction of barriers to symptom management Using the Symptom Distress Scale survey By comparison from baseline to post-intervention, there will be a 25% decrease in the barriers to symptom management among study participants. 3 months
Primary 3. Decrease in unmet needs Using the Barriers to Follow-Up Care Survey and Cancer Survivors Unmet Needs instrument By comparison from baseline to post-intervention, there will be a 25% decrease in the unmet needs among study participants. 3 months
Primary Reduction in caregiver burden using the Caregiver reaction assessment (CRA) survey By comparison from baseline to post-intervention, there will be a 25% decrease in the caregiver burden among study participants. 3 months
Primary 5. Increase knowledge and utilization of supportive services using the Medical Outcomes Study Social Support Survey By comparison from baseline to post-intervention, there will be a 25% increase in the knowledge and utilization of supportive services among study participants. 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2